SelectQuote, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023
May 11, 2023 at 02:03 am IST
Share
SelectQuote, Inc. reported earnings results for the third quarter and nine months ended March 31, 2023. For the third quarter, the company reported revenue was USD 299.4 million compared to USD 274.34 million a year ago. Net income was USD 9.26 million compared to net loss of USD 7.03 million a year ago. Basic earnings per share from continuing operations was USD 0.06 compared to basic loss per share from continuing operations of USD 0.04 a year ago. Diluted earnings per share from continuing operations was USD 0.06 compared to diluted loss per share from continuing operations of USD 0.04 a year ago.
For the nine months, revenue was USD 781.07 million compared to USD 624.66 million a year ago. Net loss was USD 10.71 million compared to USD 192.82 million a year ago. Basic loss per share from continuing operations was USD 0.06 compared to USD 1.17 a year ago. Diluted loss per share from continuing operations was USD 0.06 compared to USD 1.17 a year ago.
SelectQuote Inc. is a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for insurance products and healthcare services. The Company operates through four business lines, which include SelectQuote Senior, which provides shopping platform for Medicare Advantage and Medicare Supplement insurance plans as well as prescription drug and dental, vision, and hearing plans, and critical illness products; SelectQuote Healthcare Services, which is comprised of the SelectRx Pharmacy, a specialized medication management pharmacy; SelectQuote Life segment that provides shopping platform for life insurance products such as term life, final expense, and other ancillary products like critical illness, accidental death, and juvenile insurance, and SelectQuote Auto & Home segment provides shopping platform for auto, home, and specialty insurance lines, as well as insurance products such as homeowners, auto, dwelling fire, and other ancillary insurance products.